Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near
Originator Has Previously Outlined 45% Erosion ‘Plus-Or-Minus 10%’
Jan 13 2022
•
By
Dean Rudge
Evercore: Humira is in a strong formulary position • Source: Alexander Sánchez / Alamy Stock Photo
More from Biosimilars
More from Products
